Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2023
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical TrialAkira Kawai, Mikiya Ishihara, Tomoki Nakamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLCAtsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, et al.
Frontiers in Oncology|January 26, 2023
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinomaYuki Katsuya, Shigehisa Kitano, Makiko Yamashita, et al.
Annals of Hematology|January 15, 2022
Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphomaAkio Onishi, Shigeo Fuji, Shigehisa Kitano, et al.
Future Oncology (London, England)|October 18, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancersSara Hurvitz, Matteo Simonelli, Ramón Yarza, et al.
Journal for Immunotherapy of Cancer|July 26, 2019
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumorsKohei Shitara, Satoshi Ueha, Shigeyuki Shichino, et al.
BMJ Open|November 14, 2022
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trialSatoshi Okumura, Mikiya Ishihara, Naomi Kiyota, et al.
BMC Medicine|April 25, 2022
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TRTakayuki Ueno, Shigehisa Kitano, Norikazu Masuda, et al.
Molecular Cancer Research : MCR|January 27, 2026
Non-clear-cell renal cell carcinoma has an immune cold phenotype that impacts response to immune checkpoint inhibitorsHiroki Ishihara, Yu-Yu Liu, Riu Yamashita, et al.
Plos One|December 2, 2015
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by ChemoradiotherapyYosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2023
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical TrialAkira Kawai, Mikiya Ishihara, Tomoki Nakamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLCAtsuto Mouri, Hirotsugu Kenmotsu, Hiroshi Kagamu, et al.
Frontiers in Oncology|January 26, 2023
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinomaYuki Katsuya, Shigehisa Kitano, Makiko Yamashita, et al.
Annals of Hematology|January 15, 2022
Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphomaAkio Onishi, Shigeo Fuji, Shigehisa Kitano, et al.
Future Oncology (London, England)|October 18, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancersSara Hurvitz, Matteo Simonelli, Ramón Yarza, et al.
Journal for Immunotherapy of Cancer|July 26, 2019
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumorsKohei Shitara, Satoshi Ueha, Shigeyuki Shichino, et al.
BMJ Open|November 14, 2022
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trialSatoshi Okumura, Mikiya Ishihara, Naomi Kiyota, et al.
BMC Medicine|April 25, 2022
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TRTakayuki Ueno, Shigehisa Kitano, Norikazu Masuda, et al.
Molecular Cancer Research : MCR|January 27, 2026
Non-clear-cell renal cell carcinoma has an immune cold phenotype that impacts response to immune checkpoint inhibitorsHiroki Ishihara, Yu-Yu Liu, Riu Yamashita, et al.
Plos One|December 2, 2015
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by ChemoradiotherapyYosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi, et al.
Pageof 15